Lab-in-a-Vial Rapid Test for Internet of Things-Embedded Point-of-Healthcare Protein Biomarker Detection in Bodily...

Area of Science:

• Biomarker Discovery
• Nanotechnology
• Point-of-Care Diagnostics

Background:

• Protein biomarker detection in body fluids is challenging for non-experts.
• Existing methods like ELISA and LFA require specialized equipment and expertise.
• On-site, rapid diagnostics are needed for timely disease risk assessment.

Purpose of the Study:

• To develop a Lab-in-a-Vial (LV) platform for rapid, on-site detection and quantification of protein biomarkers.
• To enhance detection sensitivity beyond traditional diagnostic methods.
• To enable point-of-care testing (POCT) for disease risk evaluation using body fluid samples.

Main Methods:

• Utilized hydrangea-like platinum nanozymes (PtNH) within a Lab-in-a-Vial system.
• Coated vials with specific bioreceptors (antigens/antibodies) for targeted biomarker capture.
• Employed a portable wireless spectrometer for quantitative analysis.
• Validated the platform using SARS-CoV-2 antibodies and NMP22 for urothelial carcinoma detection.

Main Results:

• Achieved rapid (15-min) and accurate detection and quantification of protein biomarkers.
• Demonstrated significantly enhanced detection sensitivity (250-1300 times higher than ELISA/LFA).
• Confirmed platform effectiveness and flexibility with clinical samples (SARS-CoV-2, NMP22).

Conclusions:

• The Lab-in-a-Vial platform with PtNH offers a sensitive, rapid, and accurate solution for on-site protein biomarker diagnostics.
• This technology facilitates point-of-care testing, improving accessibility and timeliness of disease risk assessment.
• The platform shows broad applicability for various diseases with identified protein biomarkers.